Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma (RTOG 1112)
The University of Arizona Radiation Oncology Clinical Research Department is conducting a research study to evaluate the safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) followed by sorafenib in comparison with sorafenib alone in the treatment of primary liver cancer that is not surgically removable or suitable for other standard regional treatments.
If you are interested in this study you should:
- Be at least 18 years of age
- Have a diagnosis of primary liver cancer
- Recently undergone biopsy or imaging study to prove the tumor is present
- Recently had a history and physical exam
If you are interested in finding out more about this study, please call us at 520-626-6800. One of our staff will be happy to give you further information regarding this study and will schedule an appointment to allow you to discuss the study in more detail with one of our physicians. We appreciate your interest in this study and look forward to making your research experience a pleasant one. Feel free to pass this information along to anyone you think may be interested.
An Institutional Review Board responsible for human subjects research at The University of Arizona reviewed this research project and found it to be acceptable, according to applicable state and federal regulations and University policies designed to protect the rights and welfare of participants in research.